Health Canada is conducting a safety review of domperidone, a drug often prescribed off-label to breastfeeding mothers as a way to boost milk supply, after reports have alleged withdrawal symptoms and psychiatric concerns after stopping the medication.
A spokesperson for Health Canada told the Epoch Times in an emailed statement that it is “proactively” monitoring the safety of domperidone maleate.
The safety review of the drug began in December 2022 and is not expected to be completed until the summer of 2023, which Health Canada says was “prompted by domestic and foreign case reports of withdrawal symptoms after stopping or reducing the dose,” in cases where it was used to stimulate lactation, said the spokesperson….